Overlapping central and peripheral nervous system syndromes in MOG antibody–associated disorders
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received July 12, 2020
- Accepted in final form October 16, 2020
- First Published December 3, 2020.
Author Disclosures
- Simon Rinaldi, PhD, MRCP,
- Alexander Davies, PhD,
- Janev Fehmi, MSc,
- Heidi N. Beadnall, FRACP, PhD,
- Justine Wang, FRACP,
- Todd A. Hardy, FRACP, PhD,
- Michael H. Barnett, FRACP, PhD,
- Simon A. Broadley, FRACP, PhD,
- Patrick Waters, PhD, FRCPath,
- Stephen W. Reddel, FRACP, PhD,
- Sarosh R. Irani, DPhil, FRCP,
- Fabienne Brilot, PhD,
- Russell C. Dale, MRCP, PhD*,
- Sudarshini Ramanathan, FRACP, PhD*;
- the Australian and New Zealand MOG Study Group
- Simon Rinaldi, PhD, MRCP,
1. GAIN patient charity medical advisory board (unpaid) 2. ABN research council member (unpaid) 3. Inflammatory Neuropathy Consortium board member (unpaid)
NONE
1. Fresenius, travel to conference 2. Alnylam, speaker honorarium 3. argenx, speaker honorarium
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
1. Medical Research Council (UK), MR/P008399/1, Clinician Scientist Fellowship (PI), 4 years
1). University of Oxford (John Fell Fund, COVID reposes fund)
1. British Medical Association (Vera Down Grant)
NONE
NONE
NONE
NONE
NONE
NONE
- Alexander Davies, PhD,
NONE
NONE
International Association for the Study of Pain, conference attendance financial aid (2018). Biolegend, Travel grant (2019). Korean Association of Immunologists, speaker honoraria (2019).
Frontiers in Cellular Neuroscience, Guest Editor, 2020.
Named on patent application for the use of immune therapy for nerve injury.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Janev Fehmi, MSc,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) GBS/CIDP Foundation International
(1) GBS/CIDP Foundation International
NONE
NONE
NONE
NONE
NONE
NONE
- Heidi N. Beadnall, FRACP, PhD,
-Commercial entity - Novartis Advisory Board - 2020 -Commercial entity - Genzyme Advisory Boards - 2018
NONE
-Commercial entity - Biogen - Masterclass 2020 - Steering Committee and Chair -Commercial entity - Biogen - Masterclass 2019 - Steering Committee and Speaker -Commercial entity - Roche - 2019 - Speaker -Commercial entity - Biogen - Masterclass 2018 - Steering Committee and Speaker
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
-Brain Foundation Gift (Australian) - 2019 -MSBase Foundation Fellowship - 1 year Fellowship - 2019/2020
NONE
NONE
NONE
NONE
NONE
NONE
- Justine Wang, FRACP,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Todd A. Hardy, FRACP, PhD,
(1) Merck (1) Roche
NONE
NONE
(1) Advances in Clinical Neuroscience, Co-Editor, 2015- 2020
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Multiple Sclerosis Research Australia
NONE
NONE
NONE
NONE
NONE
NONE
- Michael H. Barnett, FRACP, PhD,
1.Novartis, scientific advisory board 2.Alexion,scientific advisory board
NONE
1. Merck, Conference Travel (2019 ECTRIMS)
NONE
NONE
NONE
NONE
(1) Sydney Neuroimaging Analysis Centre, (2) RxMx Corp.
NONE
NONE
NONE
1. Novartis, Research Grant support 2. Genzyme-Sanofi, Research Grant Support 3. Biogen, Research Grant Support
(1) Australian Government, CRC-P Grant, PI, 2018-2021, (2) Australian Government, MRFF Grant, PI, 2020-2023
1. MS Research Australia, Project Grant:
Nerve Research Foundation, The University of Sydney Stock/Stock Options, Medical Equipment & Materials: (1) RxMx Corp.
NONE
NONE
NONE
NONE
NONE
NONE
- Simon A. Broadley, FRACP, PhD,
(1) Alexion, (2) Biogen Idec, (3) Merck, (4) Roche, (5) NervGen, (6) Novartis, (7) Roche, (8) Sanofi
NONE
(1) Roche, speakers honoraria, (2) Merck, travel sponsorship, (3) Biogen Idec, travel sponsorship, (4) Sanofi, speakers honoraria, (5) Roche, speakers honoraria, (6) Sanofi-Genzyme, travel sponsorship, (7) Roche, travel sponsorship
(1) Multiple Sclerosis Journal - Experimental, Translational and Clinical, Editor, 0.4 years
NONE
NONE
NONE
NONE
NONE
(1) Multiple Sclerosis Research Australia, I chair the Research Management Committee (granting body) (2) Australian and New Zealand Assocaition of Neurologists, I chair the MS Neurology Group
NONE
NONE
(1) National Health and Medical Research Council, 1127819, CI, 2017-21, (2) Australian Research Council, DP180100089, CI, 2018-20, (3) National Health and Medical Research Council (Medical Research Future Fund), 1152317, CI, 2018-20
NONE
(1) Gold Coast Hospital Foundation, RGS2017-LG0003, CI, 2018- 19
NONE
NONE
NONE
NONE
NONE
NONE
- Patrick Waters, PhD, FRCPath,
Served on the advisory board for F. Hoffmann-La Roche Ltd.
NONE
Honoraria UBC and Alexion.
NONE
Assays for the detection of antibodies to LGI1, CASPR2, Tag-1 and GABA-A Receptor (g2 subunit).
NONE
NONE
NONE
NONE
NONE
NONE
Euroimmun AG
NONE
NONE
NONE
NONE
NONE
Patents for CASPR2, LGI1, TAG-1 and GABA-A Receptor (g2 subunit).
NONE
NONE
NONE
- Stephen W. Reddel, FRACP, PhD,
1. CSL 2. Baxter 3. Genzyme 4. Biogen 5. Novartis 6. National Immunoglobulin Governmental Advisory Council, Australia
NONE
1. CSL 2. Genzyme 3. Biogen 4. Lancet
NONE
NONE
NONE
NONE
1. National IVIG Governance Council of Australia
NONE
NONE
NONE
1. Genzyme 2. Grifols
NONE
NONE
1. Lambert Foundation 2. Beeren Foundation
1. Sydney Neurology 2. Medical Safety Systems
NONE
NONE
NONE
NONE
NONE
- Sarosh R. Irani, DPhil, FRCP,
Encephalitis Society and Autoimmune Encephalitis Alliance (non-profit, charity). ADC therapeutics, Immunovant and UCB (commercial)
NONE
SRI has received honoraria for speaking at scientific conferences, including the Movement Disorder Society, Dublin Neuroimunology Symposium, Korean Encephalitis meeting and Bethel Epilepsy Symposium.
NONE
SRI receives royalties on patent application WO/2010/046716 entitled 'Neurological Autoimmune Disorders'. The patent has been licensed for the development of assays for LGI1 and other VGKC-complex antibodies.
NONE
NONE
1. Commercial. MedImmune Ltd. 2. ADCT 3. Minnetronix Neuro Inc 4. UCB Pharma 5. Medicolegal projects (various)
NONE
NONE
NONE
Commercial: SRI has received research funding from UCB, CSL Behring and ONO pharmaceuticals
S.R.I has received a NIHR fellowship, Department of Health, UK to fund his DPhil/PhD
SRI received funding support from a Wellcome Intermediate Clinical Fellowship, BMA Research Grants - Vera Down grant, the Fulbright UK- US commission and the MS society (2012-2013).
NONE
NONE
NONE
For VGKC-complex antibody patent, as described above. Royalties paid by OUI.
NONE
NONE
NONE
- Fabienne Brilot, PhD,
NONE
NONE
(1) Biogen Idec, speaking honoraria (2) Merck Serono, speaking honoraria
(1)Journal of Visualized Experiments, associate editor, 5 years, no compensation received (2) Section Multiple sclerosis and Neuroimmunology, Frontiers in Immunology and Frontiers in Neurology, Associate editor, 3 years, no compensation received (3) Neurology: Neuroimmunology & Neuroinflammation, Editorial Board, 0.1 years, no compensation received
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) National Health and Medical Research Council Australia (2) Multiple Sclerosis Research Australia (MSRA)
(1) Sydney Research Excellence Initiative (The University of Sydney)
(1) The Star Scientific Foundation Australia (2) The Trish Multiple Sclerosis Foundation Australia (3) Petre Foundation Australia
NONE
NONE
NONE
NONE
NONE
NONE
- Russell C. Dale, MRCP, PhD*,
National Blood Authority. Federal, not for profit
NONE
received an honoraria for lecturing from Biogen Idec and Bristol-Myers-Squibb
Editorial advisory board member of MSARD Editorial board member of Neurology: Neuroimmunology and Neuroinflammation Editorial board member of European Journal of Paediatric Neurology
NONE
Biogen Idec honoraria in 2008 and Bristol-Myers-Squibb in 2015
NONE
NONE
NONE
NONE
NONE
NONE
NHMRC national grant in 2011 national grant for encephalitis study NHMRC practitioner fellowship 2014-8 NHMRC project grant 2015, 2018 NHMRC partnership grant 2018
Multiple Sclerosis Research Australia 2015
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Sudarshini Ramanathan, FRACP, PhD*;
Dr Ramanathan has served as a consultant on an advisory board for UCB.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Dr Ramanathan is the recipient of an National Health and Medical Research Council Early Career Fellowship, and has received research funding support from the University of Sydney in the form of an Early Career Researcher Seeding Grant
NONE
Dr Ramanathan has received research funding from the Brain Foundation (Australia) and the Petre Foundation (Australia)
NONE
NONE
NONE
NONE
NONE
NONE
- the Australian and New Zealand MOG Study Group
- From the Inflammatory Neuropathy Group (S. Rinaldi, A.D., J.F.), Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital; University of Oxford; Department of Neurology (S. Rinaldi, S.R.I.), Oxford University Hospitals NHS Foundation Trust, UK; Department of Neurology (H.N.B., M.H.B.), Royal Prince Alfred Hospital, Sydney; Brain and Mind Centre (H.N.B., T.A.H., M.H.B., S.W.R., F.B., R.C.D.), University of Sydney; Department of Neurology (J.W.), St George Hospital, Sydney; Department of Neurology (T.A.H., S.W.R., S. Ramanathan), Concord Repatriation General Hospital, Sydney; Menzies Institute of Health Queensland (S.A.B.), Griffith University; Department of Neurology (S.A.B.), Gold Coast University Hospital, Australia; Autoimmune Neurology Group (P.W., S.R.I., S. Ramanathan), Nuffield Department of Clinical Neuroscience, John Radcliffe Hospital; University of Oxford, UK; Brain Autoimmunity and Clinical Neuroimmunology Groups (F.B., R.C.D., S. Ramanathan), Kids Neuroscience Centre, Kids Research at the Children's Hospital at Westmead, Sydney; Faculty of Medicine and Health (F.B., R.C.D., S. Ramanathan), University of Sydney; School of Medical Sciences (F.B.), Discipline of Applied Medical Science, Faculty of Medicine and Health, University of Sydney, Australia; and TY Nelson Department of Paediatric Neurology (R.C.D.), Children’s Hospital at Westmead, Sydney, Australia.
- Correspondence
Dr. Ramanathan sudarshini.ramanathan{at}sydney.edu.au
Article usage
Cited By...
Letters: Rapid online correspondence
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Daniel Friedman and Dr. Sharon Chiang
► Watch
Related Articles
- No related articles found.